PL433732A1 - Zastosowanie perampanelu lub jego pochodnych w profilaktyce i leczeniu czerniaka oraz kompozycja farmaceutyczna - Google Patents
Zastosowanie perampanelu lub jego pochodnych w profilaktyce i leczeniu czerniaka oraz kompozycja farmaceutycznaInfo
- Publication number
- PL433732A1 PL433732A1 PL433732A PL43373220A PL433732A1 PL 433732 A1 PL433732 A1 PL 433732A1 PL 433732 A PL433732 A PL 433732A PL 43373220 A PL43373220 A PL 43373220A PL 433732 A1 PL433732 A1 PL 433732A1
- Authority
- PL
- Poland
- Prior art keywords
- melanoma
- application
- treatment
- perampanel
- prevention
- Prior art date
Links
- 201000001441 melanoma Diseases 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 title abstract 4
- 229960005198 perampanel Drugs 0.000 title abstract 3
- PRMWGUBFXWROHD-UHFFFAOYSA-N perampanel Chemical compound O=C1C(C=2C(=CC=CC=2)C#N)=CC(C=2N=CC=CC=2)=CN1C1=CC=CC=C1 PRMWGUBFXWROHD-UHFFFAOYSA-N 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 abstract 3
- DDOAQMGXVXFNSH-UHFFFAOYSA-N [methyl-(7-nitro-2,3-dioxo-1,4-dihydroquinoxalin-5-yl)amino]methylphosphonic acid Chemical compound CN(CP(O)(O)=O)c1cc(cc2[nH]c(=O)c(=O)[nH]c12)[N+]([O-])=O DDOAQMGXVXFNSH-UHFFFAOYSA-N 0.000 abstract 3
- ZXFRFPSZAKNPQQ-YTWAJWBKSA-N tezampanel Chemical compound C([C@@H]1C[C@@H]2C[C@H](NC[C@@H]2CC1)C(=O)O)CC=1N=NNN=1 ZXFRFPSZAKNPQQ-YTWAJWBKSA-N 0.000 abstract 3
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 abstract 2
- UQNAFPHGVPVTAL-UHFFFAOYSA-N 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+]([O-])=O)C1=C2C=CC=C1S(=O)(=O)N UQNAFPHGVPVTAL-UHFFFAOYSA-N 0.000 abstract 2
- RPXVIAFEQBNEAX-UHFFFAOYSA-N 6-Cyano-7-nitroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C(C#N)=C2 RPXVIAFEQBNEAX-UHFFFAOYSA-N 0.000 abstract 2
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 abstract 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 229950004413 becampanel Drugs 0.000 abstract 2
- MSPRUJDUTKRMLM-UHFFFAOYSA-N caroverine Chemical compound O=C1N(CCN(CC)CC)C2=CC=CC=C2N=C1CC1=CC=C(OC)C=C1 MSPRUJDUTKRMLM-UHFFFAOYSA-N 0.000 abstract 2
- 229960003355 caroverine Drugs 0.000 abstract 2
- WZMQMKNCWDCCMT-UHFFFAOYSA-N fanapanel Chemical compound FC(F)(F)C=1C=C2NC(=O)C(=O)N(CP(O)(=O)O)C2=CC=1N1CCOCC1 WZMQMKNCWDCCMT-UHFFFAOYSA-N 0.000 abstract 2
- QZULPCPLWGCGSL-UHFFFAOYSA-N irampanel Chemical compound CN(C)CCOC1=CC=CC=C1C1=NC(C=2C=CC=CC=2)=NO1 QZULPCPLWGCGSL-UHFFFAOYSA-N 0.000 abstract 2
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 abstract 2
- CHFSOFHQIZKQCR-UHFFFAOYSA-N licostinel Chemical compound N1C(=O)C(=O)NC2=C1C=C(Cl)C(Cl)=C2[N+](=O)[O-] CHFSOFHQIZKQCR-UHFFFAOYSA-N 0.000 abstract 2
- MCECSFFXUPEPDB-UHFFFAOYSA-N n-[6-(2-methylpyrazol-3-yl)-2,4-dioxo-7-propan-2-yl-1h-quinazolin-3-yl]methanesulfonamide Chemical compound CC(C)C1=CC=2NC(=O)N(NS(C)(=O)=O)C(=O)C=2C=C1C1=CC=NN1C MCECSFFXUPEPDB-UHFFFAOYSA-N 0.000 abstract 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 abstract 2
- SPXYHZRWPRQLNS-UHFFFAOYSA-N zonampanel Chemical compound [O-][N+](=O)C=1C=C2NC(=O)C(=O)N(CC(=O)O)C2=CC=1N1C=CN=C1 SPXYHZRWPRQLNS-UHFFFAOYSA-N 0.000 abstract 2
- NHYHKMQUHRGUEH-TWMKSMIVSA-N 2-ethylbutyl (3s,4ar,6r,8ar)-6-[2-(2h-tetrazol-5-yl)ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate Chemical compound C([C@@H]1C[C@@H]2C[C@H](NC[C@@H]2CC1)C(=O)OCC(CC)CC)CC1=NN=NN1 NHYHKMQUHRGUEH-TWMKSMIVSA-N 0.000 abstract 1
- RWVIMCIPOAXUDG-UHFFFAOYSA-N 6,7-dinitro-1,4-dihydroquinoxaline-2,3-dione Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+](=O)[O-])C([N+]([O-])=O)=C2 RWVIMCIPOAXUDG-UHFFFAOYSA-N 0.000 abstract 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 abstract 1
- LAKQPSQCICNZII-NOHGZBONSA-N Dasolampanel Chemical compound O([C@@H]1C[C@@H]2C[C@H](NC[C@@H]2CC1)C(=O)O)C1=CC=CC(Cl)=C1C1=NN=NN1 LAKQPSQCICNZII-NOHGZBONSA-N 0.000 abstract 1
- COXVTLYNGOIATD-UHFFFAOYSA-N Evans blue free acid Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C(N)C2=C(O)C(N=NC3=CC=C(C=C3C)C=3C=C(C(=CC=3)N=NC=3C(=C4C(N)=C(C=C(C4=CC=3)S(O)(=O)=O)S(O)(=O)=O)O)C)=CC=C21 COXVTLYNGOIATD-UHFFFAOYSA-N 0.000 abstract 1
- LFBZZHVSGAHQPP-UHFFFAOYSA-N GYKI 52466 Chemical compound C12=CC=3OCOC=3C=C2CC(C)=NN=C1C1=CC=C(N)C=C1 LFBZZHVSGAHQPP-UHFFFAOYSA-N 0.000 abstract 1
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 abstract 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 abstract 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 abstract 1
- 229940125717 barbiturate Drugs 0.000 abstract 1
- 229950002865 dasolampanel Drugs 0.000 abstract 1
- YEUPBRRGMWBCEB-UHFFFAOYSA-N dnqx Chemical compound O=C1C(=O)N=C2C=C([N+]([O-])=O)C([N+](=O)[O-])=CC2=N1 YEUPBRRGMWBCEB-UHFFFAOYSA-N 0.000 abstract 1
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 abstract 1
- 229960000305 enflurane Drugs 0.000 abstract 1
- 229960003699 evans blue Drugs 0.000 abstract 1
- 229950005202 fanapanel Drugs 0.000 abstract 1
- 229950010390 irampanel Drugs 0.000 abstract 1
- 229950010467 licostinel Drugs 0.000 abstract 1
- 229960001412 pentobarbital Drugs 0.000 abstract 1
- 239000008024 pharmaceutical diluent Substances 0.000 abstract 1
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 abstract 1
- 229960000249 pregnenolone Drugs 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229950004454 selurampanel Drugs 0.000 abstract 1
- 229950004608 talampanel Drugs 0.000 abstract 1
- 229950000075 tezampanel Drugs 0.000 abstract 1
- 229940026510 theanine Drugs 0.000 abstract 1
- 229960003279 thiopental Drugs 0.000 abstract 1
- 229960004394 topiramate Drugs 0.000 abstract 1
- 229950007059 zonampanel Drugs 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Przedmiotem zgłoszenia jest perampanel i jego pochodne do zastosowania w zapobieganiu powstawaniu lub leczeniu czerniaka. Zgłoszenie dotyczy też kompozycji farmaceutycznej do stosowania na skórę w profilaktyce i leczeniu czerniaka zawierająca substancję czynną w połączeniu z co najmniej jednym nośnikiem lub rozcieńczalnikiem farmaceutycznym znamienna tym, że jako substancję czynną zawiera perampanel lub jego pochodne. Przedmiotem zgłoszenia jest także selektywny antagonista AMPA, wybrany z grupy: bekampanel (becampanel, AMP397), dasolampanel (NGX-426), fanapanel (ZK-200775), irampanel (BIIR-561), selurampanel (BGG492), talampanel (GYKI 537773; LY300164), tezampanel (LY-293,558, NGX-424), zonampanel (YM872), do zastosowania w zapobieganiu powstawaniu lub leczeniu czerniaka oraz nieselektywny antagonista AMPA, wybrany z grupy: barbiturany (pentobarbital, tiopental), błękit Evansa (T-1824), CNQX (cyanquixaline), cyklopropan (cyclopropane), DNQX (6,7-dinitroquinoxaline-2,3-dione), enfluran, filantotoksyny (philanthotoxins), GYKI-52466, karoweryna (caroverine), kwas kynureninowy, licostinel (ACEA-1021), NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline), pregnenolon, teanina(γ-L-glutamylethylamide), topiramat, do zastosowania w zapobieganiu powstawaniu lub leczeniu czerniaka.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL433732A PL243152B1 (pl) | 2020-04-28 | 2020-04-28 | Zastosowanie perampanelu w profilaktyce i leczeniu czerniaka oraz kompozycja farmaceutyczna |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL433732A PL243152B1 (pl) | 2020-04-28 | 2020-04-28 | Zastosowanie perampanelu w profilaktyce i leczeniu czerniaka oraz kompozycja farmaceutyczna |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL433732A1 true PL433732A1 (pl) | 2021-11-02 |
| PL243152B1 PL243152B1 (pl) | 2023-07-10 |
Family
ID=78595286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL433732A PL243152B1 (pl) | 2020-04-28 | 2020-04-28 | Zastosowanie perampanelu w profilaktyce i leczeniu czerniaka oraz kompozycja farmaceutyczna |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL243152B1 (pl) |
-
2020
- 2020-04-28 PL PL433732A patent/PL243152B1/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL243152B1 (pl) | 2023-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Amrollahi et al. | Double-blind, randomized, placebo-controlled 6-week study on the efficacy and safety of the tamoxifen adjunctive to lithium in acute bipolar mania | |
| AU2017276155B2 (en) | Combination therapy with an antitumor alkaloid | |
| EP4491199A3 (en) | Gadolinium bearing pcta-based contrast agents | |
| Kahn et al. | L-5-Hydroxytryptophan in the treatment of anxiety disorders | |
| Steers et al. | Assessment of the efficacy and safety of Viagra®(sildenafil citrate) in men with erectile dysfunction during long-term treatment | |
| Sobhy et al. | Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males | |
| CN101785751B (zh) | 用于一次性卫生用品的缓释清凉剂和制备方法及应用 | |
| Önder et al. | A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake | |
| MA34655B1 (fr) | Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse | |
| PL433732A1 (pl) | Zastosowanie perampanelu lub jego pochodnych w profilaktyce i leczeniu czerniaka oraz kompozycja farmaceutyczna | |
| Melena et al. | The effect of topical diltiazem on the intraocular pressure in betamethasone-induced ocular hypertensive rabbits | |
| JP2009102303A (ja) | 性の健康増強の達成に有用な無水組成物 | |
| Angelopoulos et al. | Changes in central serotonergic function as a correlate of duration of illness in paranoid schizophrenia | |
| Ruilope et al. | Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomized trial: the EDICTA study | |
| BRPI0414777A (pt) | compostos, composições farmacêuticas, uso de um ou mais compostos, e, método de tratar um paciente que sofre de um distúrbio | |
| WO2018224736A3 (en) | THERAPEUTICALLY ACTIVE STEROID DERIVATIVES | |
| PL433733A1 (pl) | Zastosowanie perampanelu w leczeniu chorób skóry oraz kompozycja farmaceutyczna | |
| PL430029A1 (pl) | Kompozycja doustna zawierająca beta-escynę do obniżania toksyczności acetaldehydu | |
| Garcia-Borreguero et al. | Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A | |
| Gitlin | Treatment-resistant bipolar disorder | |
| Hoff et al. | Cimoxaton and Moclobemid, Two New MAO-lnhibitors: Influence on Sleep Parameters in Patients with Major Depressive Disorder | |
| Dominguez et al. | Demographics, prevalence, and clinical features of the schizo-obsessive subtype of schizophrenia | |
| Cassidy et al. | Combined catecholamine and indoleamine depletion following response to ECT | |
| Amsterdam et al. | Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial | |
| Aravantinos et al. | A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group Study |